Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Balancing Act: All Eyes on Nesp Biosame Pricing before June 2019 Listing, Biosimilars to Follow in November
November 5, 2018
- Opdivo-Yervoy Combo Gets RCC Nod in Taiwan
November 5, 2018
- Kyowa Kirin to Start US PI Study on IDO Inhibitor-Bavencio Combo
November 5, 2018
- 8 Major Drug Makers See Flat Sales in 1st Half; Overseas Growth Continues to Compensate for Slumping Japan Revenue
November 5, 2018
- Pfizer Files Vyndaqel for Sakigake-Designated Transthyretin Amyloid Cardiomyopathy Indication in Japan
November 5, 2018
- JCR’s Fabrazyme Biosimilar to Enter NHI Price List as Early as November
November 5, 2018
- Takeda Unveils Estimated Net Debt, Goodwill Post Shire Integration
November 2, 2018
- Eisai, Merck to Start Lenvima Commercial Collaboration in Major Markets by March-End
November 2, 2018
- Eisai’s 1st Half Operating Profit Zooms 74% on Lenvima Boon
November 2, 2018
- Ono Plans to File Opdivo for 2nd-Line Esophageal Cancer by March-End
November 2, 2018
- Ono Racks Up 19% Revenue Rise on Positive Opdivo Sales
November 2, 2018
- Ribomic Launches PI/IIa Study of Anti-FGF2 Aptamer in US for AMD
November 2, 2018
- Astellas Investing 30 Billion Yen in R&D, Production Facilities Catering to Multiple Modalities
November 1, 2018
- Japan Needs New Pricing Model for Gene Therapies: Astellas Chief
November 1, 2018
- Astellas Sales Rep Number Now at 2,100; Redundancy Program Gets Underway
November 1, 2018
- Daiichi Sankyo Pushes Back Profit Target in 5-Year Plan, Eyes Intensive Investment in Oncology
November 1, 2018
- Chugai Drops Herceptin Patent Suits against Daiichi Sankyo, Pfizer
November 1, 2018
- Daiichi Sankyo’s Half-Year Revenue Fell 4.8% as Generics Sap Olmesartan Sales
November 1, 2018
- Takeda Unveils Post-Acquisition Executive Team, 2 of 20 Members from Shire
November 1, 2018
- Takeda Sees Flat Sales as Brisk US Revenue Offset by Off-Patent Divestiture
November 1, 2018
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…